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[Ag2(9-aca)2] (9-acaH = 9-anthracenecarboxylic acid) interacts with DMSO and a selection of substituted
imidazoles giving [Ag4(DMSO)4(9-aca)4]n (1), [Ag(2-Me-imH)2(9-aca)] (2), [Ag(4-Ph-imH)2(9-aca)] (3),
[Ag(2-Mebenz-imH)2(9-aca)] (4), [Ag(2-Mebenz-im)] (6), [Ag(Benz-im)] (7), [Ag(2-Ph-im)] (8) and
[Ag(4,5-CN-im)] (9) (2-Me-imH = 2-methylimidazole; 4-Ph-imH = 4-phenylimidazole; 2-Mebenz-
imH = 2-methylbenzimidazole; Benz-imH = benzimidazole; 2-Ph-imH = 2-phenylbenzimidazole; 4,5-
CN-imH = 4,5-dicyanoimidazole). In the carboxylate/imidazole complexes 2–4, the imidazole ligand is
in the neutral form, whilst in complexes 6–9 the imidazolate ligand is deprotonated and no carboxylate
ligand is present. Attempted recrystallization of 4 from EtOH gives the metal-free, imidazolium salt, 2-
Mebenz-imH2)(9-aca)H2O (5). The X-ray crystal structures of complexes 1 and 2 and the salt 5 were
determined. Antimicrobial screening showed that the Ag(I) complexes were substantially more active
against the fungus Candida albicans than the bacterial species, methicillin-resistant Staphylococcus aureus
(MRSA) and Escherichia coli. Some of the complexes offer a good prognosis for Galleria mellonella (larvae of
the greater wax moth) infected with a lethal dose of C. albicans cells.
 2013 Elsevier Ltd. All rights reserved.1. Introduction aureus and Bacillus spizizenii. Ag(I) complexes containing imidazoleRecent World Health Organization (WHO) publications [1,2]
have highlighted the critical situation of antimicrobial drug resis-
tance and that too few new compounds are being developed to
combat infectious agents. In a recent publication, Lansdown chron-
icles the uses of silver-containing therapeutics in the treatment of
bacterial, fungal and viral infections [3]. Besides its high bacterici-
dal and fungicidal attributes, and in stark contrast to most other
medicinally-active transition metal ions, Ag(I) ions are relatively
well tolerated by mammalian cells [4].
It has been reported that coordinating imidazole and deriva-
tised imidazoles to a Ag(I) centre generally enhances the antimi-
crobial effects of the metal ion. For example, Kleyi et al. [5]
studied the antimicrobial activity of a family of 2-hydroxy-
methyl-N-alkylimidazole ligands and their Ag(I) complexes and
found that whereas the metal-free ligands were poorly active
against Escherichia coli and Candida albicans, imidazoles with long
pendant alkyl chains displayed high activity against Staphylococcusll rights reserved.ligands with shorter alkyl chains were more active against E. coli,
whilst those with longer chains displayed higher activity against
B. spizizenii. The authors attributed the antimicrobial effect on
E. coli and C. albicans solely to the Ag(I) ions since the metal-free
ligands displayed poor activity against these organisms. They also
concluded that the activity of the complexes containing ligands
with longer alkyl chain lengths was due to a combination of the
Ag(I) ion and the active imidazole.
We have previously synthesised and screened mononuclear,
multinuclear and polymeric Ag(I) complexes comprising imidazole
and N1-substituted imidazoles, and found that [Ag(imH)2.3(CH3-
CN)0.7](9-aca), [Ag6(imH)4(9-aca)6(MeOH)2], {[Ag(1-Me-im)2]2[-
Ag4(9-aca)6]}, {[Ag(1-Bu-im)2]2[Ag4(9-aca)6]} and [Ag(apim)](9-
aca)H2O (imH = imidazole; 1-Me-im = 1-methylimidazole; 1-Bu-
im = 1-butylimidazole; apim = 1-(3-aminoproply)imidazole; 9-
acaH = 9-anthracenecarboxylic acid) were all highly active,
in vitro, against E. coli, S. aureus and C. albicans cells [6]. Moreover,
in vivo studies conducted on larvae of the greater wax moth (Gal-
leria mellonella) infected with a lethal dose of C. albicans cells re-
vealed that pre- and post-administration of some of these Ag(I)
complexes increased the chances of survival of the juveniles.
Encouraged by these results, [Ag2(9-aca)2] has now been used as
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Fig. 1. Ligand structures.
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complexes containing relatively cheap, commercially available
imidazole ligands carrying substituents at positions other than
the pyrrole-type N1 atom of the ring (Fig. 1). In addition to their
structural and physical properties, the in vitro and in vivo antimi-
crobial activities of the complexes are also reported.2. Experimental
2.1. Reagents and instrumentation
Chemicals were purchased from commercial sources and were
used without further purification. The syntheses of all silver com-
plexeswere conducted in the absence of light and the productswere
stored in the dark at all times. [Ag2(9-aca)2]was prepared fromK+(9-
aca)- and AgNO3 in accordancewith the literaturemethod [6]. Infra-
red spectra (as KBr discs) were recorded in the region 4000–
370 cm1 on a Perkin Elmer System 2000 FT spectrometer. 1H
NMR spectra, recorded as solutions in deuterated dimethylsulfoxide
((CD3)2SO), were recorded on a Bruker Avance spectrometer operat-
ing at 300 MHz and a probe temperature of 25 C. MicroanalyticalTable 1
X-ray crystallographic data.
Compound 1
Formula [Ag4(DMSO)4(9-aca)4]n
Empirical formula C68H60Ag4O12S4
Crystal system monoclinic
Space group P21/c
Unit cell dimension
a (Å) 9.1304(7)
b (Å) 19.5875(14)
c (Å) 18.0502(13)
b () 99.2280(10)
V (Å3) 3186.3(4)
Z 2
F(000) 1632
Crystal size (mm3) 0.41  0.09  0.08
Crystal description yellow rod
Refl collected 30770
Unique reflection (Rint) 7311 (0.0426)
% Complete (to h) 99.9 (27.50)
Data/restraints/param 7311/711/518
Goodness-of-fit (GOF) on F2 1.027
R1, wR2 [I > 2r(I)] 0.0318, 0.0702
R1, wR2 (all data) 0.0463, 0.0770
Residuals (e Å3) 0.821, 0.668data were provided by the Microanalytical Laboratory, University
College Dublin, Belfield, Dublin 4, Ireland.
2.2. X-ray crystal structure determinations
X-ray crystallographic data (Table 1) were collected at 150(2) K
on a Bruker APEX II diffractometer using Mo Ka radiation
(k = 0.71073 Å) and semi-empirical absorption corrections were
applied. The structures were solved by direct methods and refined
on F2 using all the reflections [7]. All of the non-hydrogen atoms
were refined using anisotropic atomic displacement parameters.
All hydrogen atoms were inserted at calculated positions using a
riding model except for those bonded to oxygen or nitrogen in
compound 3; these were located from difference maps and refined
under geometric restraints. One of the two independent 9-aca
groups in complex 1 was disordered, this was modelled as 60:40
occupancy of two overlapping sites.
2.3. Biological screening
E. coli, MRSA, C. albicans and G. mellonella (larvae of the greater
wax moth) were sourced and stored as previously described [6].2 5
[Ag(4-Ph-imH)2(9-aca)] (2-Mebenz-imH2)(9-aca)H2O
C23H21AgN4O2 C23H20N2O3
monoclinic orthorhombic
C2/c P212121
19.8374(17) 6.9251(8)
15.2507(13) 14.8341(17)
14.4941(13) 18.522(2)
110.140(1) 90
4116.8(6) 1902.7(4)
8 4
2000 784
0.28  0.14  0.13 0.41  0.08  0.08
colourless pyramid colourless rod
20857 16919
5142 (0.0541) 2241 (0.0507)
99.9 (28.35) 99.9 (26.35)
5142/0/273 2241/0/260
1.030 1.046
0.0345, 0.0715 0.0365, 0.0853
0.0541, 0.0787 0.0482, 0.0917
0.680, 0.407 0.308, 0.355
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and antifungal properties of the complexes [6]. G. mellonella were
utilised to assess the in vivo toxicity of the complexes and to estab-
lish fungal pathogenicity [6,8,9]. Two in vivo antifungal treatment
protocols were used to determine fungal pathogenicity [6]. For
the prophylactic treatment, larvae were injected with a solution/
suspension of the test complex and after 1 h they were inoculated
with a lethal dose of C. albicans cells. For the treatment of infection,
larvae were first inoculated with a lethal dose of fungal cells and
after 1 h the test solution/suspension was administered. Larvae
survival was monitored 72 h following the treatment protocols.
2.4. Chemical synthesis
2.4.1. [Ag4(DMSO)4(9-aca)4]n (1)
[Ag2(9-aca)2] (0.100 g, 0.15 mmoles) was dissolved in dimethyl-
sulfoxide (4 cm3) and the mixture heated to 80 C for 20 min. Eth-
anol (15 cm3) was added and the solution was brought to reflux
and then filtered. The filtrate was left to stand and after 3 days yel-
low, needle-like crystals were collected by filtration, washed with
ethanol and allowed to air-dry (0.062 g yield 50%). Soluble in MeCN
and DMSO. Molecular weight 814.44 g mol1. Anal. Calc.: C, 50.14;
H, 3.71. Found: C, 50.22; H, 3.70%. IR (cm1): 3411, 3050, 1620,
1587, 1565, 1538, 1427, 1389, 1320, 1276, 1018. 1H NMR (d,
DMSO): 8.45 (s, 1H); 8.18 (m, 2H); 8.05 (m, 2H); 7.48 (m, 4H);
2.56 (s, 6H).
2.4.2. [Ag(2-Me-imH)2(9-aca)] (2)
[Ag2(9-aca)2] (0.068 g, 0.10 mmoles) was dissolved in acetoni-
trile (10 cm3) and a solution of 2-methylimidazole (0.035 g,
0.40 mmoles) in acetonitrile (2 cm3) was added dropwise with stir-
ring. A white precipitate immediately formed which quickly redis-
solved. The solution was stirred for 1 h at room temperature and a
yellow precipitate formed. The yellow solid was collected by filtra-
tion, washed with a small portion of ethanol and diethyl ether. The
yellow solid was recrystallised from acetonitrile to yield light-yel-
low crystals suitable for X-ray crystal analysis (0.050 g yield 51%).
Soluble in MeOH, EtOH, MeCN and DMSO. Molecular weight:
493.31 g mol1. Anal. Calc.: C, 56.00; H, 4.29; N, 11.36. Found: C,
55.70; H, 4.29; N, 11.08%. IR (cm1): 3047, 2909, 2855, 2685,
1590, 1554, 1484, 1422, 1386, 1358, 1318, 1275, 1166, 1130,
1113, 1013. 1H NMR (d, DMSO): 8.43 (s, 1H); 8.20 (m, 2H); 8.08
(m, 2H); 7.50 (m, 4H); 7.08 (s, 4H); 2.47 (s, 6H).
2.4.3. [Ag(4-Ph-imH)2(9-aca)] (3)
[Ag2(9-aca)2] (0.658 g, 1.00 mmoles) was dissolved in hot aceto-
nitrile (100 cm3) and the solution was filtered to remove any
undissolved material. 4-Phenylimidazole (0.438 g, 3.04 mmoles)
was dissolved in hot acetonitrile and added to the hot solution of
[Ag2(9-aca)2]n. The mixture was stirred at room temperature for
0.5 h. The suspension was filtered and the beige precipitate was
washed with a small portion of cold ethanol and air-dried
(0.887 g yield 81%). Soluble in DMSO. Molecular weight:
473.32 g mol1. Calc.: C, 64.19; H, 4.08; N, 9.07%. Found: C,
63.74; H, 4.14; N, 8.88%. IR (cm1): 3430, 3280, 3129, 3057,
2977, 2821, 2709, 2633, 1614, 1579, 1553, 1495, 1442, 1424,
1387, 1355, 1318, 1273, 1180, 1136, 1073, 1029, 1012. 1H NMR
(d, DMSO): 8.47 (s, 1H); 8.14 (m, 2H); 8.06 (m, 2H); 7.88 (s, 2H);
7.83 (s, 4H); 7.59 (s, 2H); 7.48 (m, 4H); 7.39 (t, 4H); 7.25 (t, 2H).
2.4.4. [Ag(2-Mebenz-imH)2(9-aca)] (4)
[Ag2(9-aca)2] (1.000 g, 1.52 mmoles) was dissolved in hot aceto-
nitrile (100 cm3) and the solution was filtered to remove any
undissolved material. The filtrate was brought to reflux and a solu-
tion of 2-methylbenzimidazole (0.804 g, 6.08 mmoles) in hot ace-
tonitrile (30 cm3) was added. A white precipitate immediatelyformed. The suspension was removed from the heat source and
was stirred at room temperature for 1 h. The beige solid was fil-
tered off, washed with a small portion of cold ethanol and air-dried
(1.562 g yield 87%). Soluble in hot MeOH and DMSO. Molecular
weight: 461.32 g mol1. Anal. Calc.: C, 62.74; H, 4,25; N, 9.44.
Found: C, 62.40; H, 4.17; N, 9.44%. IR (cm1): 3446, 3047, 2524,
1888, 1625, 1599, 1558, 1532, 1456, 1427, 1388, 1318, 1282,
1223, 1041, 1005. 1H NMR (d, DMSO): 8.63 (s, 1H); 8.09 (m, 2H);
8.03 (s, 2H); 7.56 (m, 4H); 7.49 (m, 4H); 7.15 (m, 4H). The signal
for the protons of the methyl groups are masked by the large resid-
ual peak for non-deuterated DMSO (ca. 2.5 ppm).
2.4.5. (2-Mebenz-imH2)(9-aca)H2O (5)
In an attempt to recrystallise [Ag(2-Mebenz-imH)2(9-aca)] (4)
from ethanol the silver-free, monohydrate salt, (5), crystallised
and was subsequently characterised using X-ray crystallography.
2.4.6. [Ag(2-Mebenz-im)] (6)
[Ag2(9-aca)2] (0.500 g, 0.76 mmoles) was suspended in metha-
nol (50 cm3) at room temperature. 2-Methylbenzimidazole
(0.201 g, 1.52 mmoles) was dissolved in methanol (10 cm3) and
added to the stirring suspension of [Ag2(9-aca)2]. The mixture
was heated and a beige precipitate formed. The solid was filtered
while hot, washed with methanol and allowed to air-dry (0.288 g
yield 79%). Insoluble in water and all common solvents. Molecular
weight: 239.04 g mol1. Anal. Calc.: C, 40.19; H, 2.96; N, 11.72.
Found: C, 40.27; H, 2.97; N, 11.24%. IR (cm1): 3434, 3056, 3025,
2915, 1868, 1751, 1608, 1579, 1473, 1448, 1397, 1285, 1226,
1148, 1110, 1076, 1002.
2.4.7. [Ag(Benz-im)] (7)
[Ag2(9-aca)2] (0.200 g, 0.30 mmoles) was suspended in metha-
nol (40 cm3) at room temperature and a solution of benzimidazole
(0.072 g, 0.60 mmoles) in methanol (5 cm3) was added to the sus-
pension. A beige precipitate formed and the suspension was stirred
at room temperature for 0.5 h. The beige solid was filtered, washed
with cold methanol and air-dried (0.093 g yield 68%). Insoluble in
water and all common solvents. Molecular weight: 225.01 g mol1.
Anal. Calc.: C, 37.36; H, 2.24; N, 12.45. Found: C, 37.65; H, 2.29; N,
11.97%. IR (cm1): 3443, 3073, 1759, 1609, 1584, 1463, 1453, 1365,
1300, 1281, 1239, 1185, 1145, 1113, 1015, 999.
2.4.8. [Ag(2-Ph-im)] (8)
[Ag2(9-aca)2] (0.500 g, 0.76 mmoles) was dissolved in hot aceto-
nitrile (40 cm3) and the solution was filtered to remove any undis-
solved material. 2-Phenylimidazole (0.219 g, 1.52 mmoles) was
dissolved in hot acetonitrile (20 cm3) and this was added to the
hot [Ag2(9-aca)2] solution. The resulting suspension was stirred
at room temperature for 0.25 h. The beige precipitate was filtered,
washed with ethanol and air-dried (0.246 g yield 64%). The com-
plex was only slightly soluble in DMSO.
Molecular weight: 251.05 g mol1. Anal. Calc.: C, 43.06; H, 2.82;
N, 11.16. Found: C, 43.62; H, 2.81; N, 10.58%. IR (cm1): 3445,
3040, 1601, 1578, 1482, 1458, 1413, 1318, 1298, 1280, 1147,
1074, 1023. 1H NMR (d, DMSO): 7.92 (d, 2H); 7.41 (t, 2H); 7.33
(m, 1H); 7.24 (s, 1H); 7.02 (s, 1H).
2.4.9. [Ag(4,5-CN-im)] (9)
[Ag2(9-aca)2] (0.500 g, 0.76 mmoles) was dissolved in hot aceto-
nitrile (50 cm3) and the solution filtered to remove any undis-
solved material. 4,5-Dicyanoimidazole (0.359 g, 3.04 mmoles)
was dissolved in acetonitrile (5 cm3) and added to the hot
[Ag2(9-aca)2] solution. A beige precipitate immediately formed
and the suspension was stirred at room temperature for 1 h. The
beige solid was filtered, washed with a small portion of cold etha-
nol and air-dried (0.240 g yield 70%). Insoluble in water and all
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26.69; H, 0.49; N, 24.91. Found: C, 26.62; H, 0.41; N, 24.59%. IR
(cm1): 3534, 2227, 2176, 1748, 1720, 1583, 1492, 1471, 1457,
1438, 1321, 1303, 1283, 1250, 1115, 1105, 958, 878, 861.3. Results and discussion
3.1. Synthesis and characterization
In our previous work [6] involving the reaction of [Ag2(9-aca)2]
with imidazole and imidazoles substituted at the 1-position (pyr-
role-type nitrogen, N1), it was found that slight changes in either
the reaction solvent or the structure of the imidazole ligand had
a marked and somewhat unpredictable effect on the composition
of the isolated complex. An overriding structural theme amongst
the complexes [Ag(imidH)2.3(CH3CN)0.7](9-aca), [Ag6(imidH)4(9-
aca)6(MeOH)2], {[Ag(1-Me-im)2]2[Ag4(9-aca)6]} and {[Ag(1-Bu-
im)2]2[Ag4(9-aca)6]}, was the prevelance of bis(imidazole)silver(I)
entities, in which two neutral imidazole ligands coordinate via
their imine N-atoms in an almost linear N–Ag–N fashion. Similarly,
[Ag(apim)](9-aca)H2O [6] and [Ag(apim)]ClO4 [10] had the imine
nitrogen of one apim and the nitrogen of the pendant amine func-
tion of a neighbouring apim coordinated to the metal centre, with
the N–Ag–N bond angle within the polymeric framework being ca.
177. Additionally, the imidazole ligands in [Ag(imH)2.3(CH3-
CN)0.7](9-aca) and [Ag6(imH)4(9-aca)6(MeOH)2] coordinate as neu-
tral molecules (pyrrole N1 not deprotonated). In the present work,
where [Ag2(9-aca)2] has been reacted with a range of imidazoles
bearing substituents at positions other than N1, it is again apparent
that relatively minor variations in the structure of the incoming
imidazole ligand, and in some cases the reaction solvent, can dra-
matically affect product formulation. Furthermore, some of the
imidazoles are seen to deprotonate at the pyrrole N1 atom to give
a heterocyclic, anionic ligand and thus eliminating the requirement
for a 9-aca anion.
Synthetic routes to the new complexes are summarised in
Scheme 1. [Ag4(DMSO)4(9-aca)4]n (1) was readily prepared in 50%
yield by heating [Ag2(9-aca)2] in DMSO and ethanol (Scheme 1).
The X-ray crystal structure of 1 was determined (Table 1) and se-
lected bond lengths and angles are given in Table 2. Although the
asymmetric unit is {Ag2(9-aca)2(DMSO)2}, the complex is probably
better described as a polymermade up of centrosymmetric tetranu-
clear [Ag4(9-aca)4(DMSO)2] units linked into chains by bridging two
further DMSO ligands (Fig. 2). The short Ag1–Ag2 and longer Ag1–
Ag10 bond lengths in 1 (2.9144(4) and 3.1468(5) Å, respectively)
contrastwith short and longmetal–metal distances in thepolymeric[Ag2(9-aca
(2-Mebenz-imH2)(9-aca)·H2O (5)
[Ag(2-Mebenz-imH)2(9-aca)] (4)
[Ag4(DMSO)4(9-aca)4]n (1)
[Ag(2-Mebenz-im)] (6) [Ag(Benz-im)] (7)
EtOH
2-Mebenz-imH
MeCN
DMSO
EtOH
2-Mebenz-imH
MeOH Benz-imH
MeOH
Schemestarting material, [Ag2(9-aca)2] (2.8508(9) and 3.657(1) Å, respec-
tively) [11]. In 1, each carboxylate group forms a l-1,3-bridge be-
tween Ag1 and Ag2, additionally O11 is a single atom bridge
between Ag1 and Ag10 while O31 and O32 bind to Ag1 in chelate
fashion. The DMSO ligand containing O1 bridges Ag1 and Ag20 with-
in a tetranuclear subunit and the second DMSO, which contains O2,
links theseunits into chains runningparallel to the a axis by bridging
Ag2 and Ag200 (Fig. 3). The average Ag–O bonds for the carboxylate
and DMSO ligands in 1 are similar (2.423 and 2.448 Å, respectively),
but are both somewhat longer than the Ag–O(carboxylate) bonds in
[Ag2(9-aca)2] (average 2.293 Å for the carboxylate bridging biden-
tate and O-bridging bonds). These longer metal–oxygen (carboxyl-
ate) bond lengths in 1 may be a consequence of the increased
number of donor atoms (increased electron density) surrounding
the metal centres.
The IR spectrum of 1 is very similar to that of [Ag2(9-aca)2] apart
from the inclusion of the bands associated with the DMSO ligands.
A band is observed at 708 cm1 for the symmetric stretching vibra-
tion of the S@O moiety along with a strong band at 955 cm1 cor-
responding to the S–CH3 rocking vibration of the methyl groups
[12]. The carboxylate m(OCO)asym and m(OCO)sym stretching vibrations
occur at 1587 and 1427 cm1, respectively, giving a D(OCO) value of
160 cm1. Using this value it is not possible to identify the carbox-
ylate coordination mode as predictions with D(OCO) values of ca.
165 cm1 have been shown to be untrustworthy [13].
The 1H NMR spectrum of the starting material, [Ag2(9-aca)2],
which exhibits peaks for the aromatic protons at 8.44 (s, 2H),
8.18 (m, 4H), 8.03 (m, 4H) and 7.47 ppm (m, 8H), is very similar
to that of [Ag4(DMSO)4(9-aca)4]n (1), the only difference being
the presence of a singlet at 2.56 ppm for the methyl groups of
the DMSO ligands. It is believed that the DMSO ligands dissociate
in solution as the position of this singlet is unchanged when com-
pared to uncoordinated DMSO. Coordination to the silver ion is ex-
pected to cause a shielding of the DMSO methyl protons but this is
not evident from the spectrum.
[Ag(2-Me-imH)2(9-aca)] (2) was synthesised from [Ag2(9-aca)2]
and 2-methylimidazole (2-Me-imH) in 51% yield using acetonitrile
as the reaction solvent (Scheme 1). Complex 2 was recrystallised
from acetonitrile and the X-ray crystal structure solved (Figs. 4–6
and Table 2). In 2, the Ag(I) ion is coordinated to the imine nitrogen
atoms of the two imidazole rings and also to one carboxylate oxy-
gen atom of the anthracene ligand. This monodentate Ag–O bond
length (2.4941(19) Å) is significantly longer than the average Ag–
O distance for the bridging bidentate and O-bridging bonds in
[Ag2(9-aca)2] (2.293 Å). The average Ag–N bond length in 2
(2.113 Å) is similar to that found for the ordered, transoid imida-
zoles in [Ag(imH)2.3(CH3CN)0.7](9-aca) (2.126 Å) and also to the)2]
[Ag(4-Ph-imH)2(9-aca)] (3)
[Ag(2-Me-imH)2(9-aca)] (2)
[Ag(2-Ph-im)] (8) [Ag(4,5-CN-im)] (9)
2-Me-imH
MeCN
4-Ph-imH
MeCN
2-Ph-imH
MeCN
4,5-CN-imH
MeCN
1.
Table 2
Selected bond lengths (Å) and angles ().
[Ag4(DMSO)4(9-aca)4]n (1)a
Ag1–O11 2.357(2)
Ag1–O31 2.384(2)
Ag1–O110 2.421(2)
Ag1–O1 2.428(2)
Ag1–O32 2.598(2)
Ag1–Ag2 2.9144(4)
Ag2–O12 2.358(2)
Ag2–O200 2.4005(19)
Ag2–O32 2.421(2)
Ag2–O2 2.467(2)
Ag2–O10 2.500(2)
Ag1–Ag10 3.1468(5)
O11–Ag1–O31 110.87(9)
O11–Ag1–O110 97.62(6)
O31–Ag1–O110 151.25(9)
O11–Ag1–O1 90.50(8)
O31–Ag1–O1 99.46(8)
O110–Ag1–O1 83.58(7)
O11–Ag1–O32 117.64(7)
O110–Ag1–O32 111.16(7)
O1–Ag1–O32 144.60(7)
O12–Ag2–O200 101.68(7)
O12–Ag2–O32 111.82(8)
O200–Ag2–O32 104.96(7)
O12–Ag2–O2 165.32(8)
O200–Ag2–O2 81.11(7)
O32–Ag2–O2 80.90(7)
O12–Ag2–O10 83.63(8)
O200–Ag2–O10 108.51(7)
O32–Ag2–O10 139.17(7)
O2–Ag2–O10 81.83(7)
Ag1–O1–Ag20 104.22(8)
Ag200–O2–Ag2 98.88(7)
Ag1–O11–Ag10 82.38(6)
Ag2–O32–Ag1 70.90(6)
[Ag(2-Me-imidH)2(9-aca)] (2)b
Ag1–N31 2.111(2)
Ag1–N21 2.115(2)
Ag1–O1 2.4941(19)
N22  O20 2.764(3)
N31–Ag1–N21 162.07(9)
N31–Ag1–O1 96.93(8)
N21–Ag1–O1 101.00(8)
N32  O200 2.779(3)
(2-Mebenz-imidH)(9-aca)H2O (5)c
N1  O1W 2.654(3)
N2  O10 2.651(3)
O1W  O200 2.724(3)
O1W  O1 2.731(3)
a Symmetry transformations used to generate equivalent atoms: ‘=x + 1, y + 1,
z + 1; ‘‘=x, y + 1, z + 1.
b Symmetry transformations used to generate equivalent atoms: ‘=x + 1/2,
y + 1/2, z + ½; ‘‘=x, y, z + 1/2.
c Symmetry transformations used to generate equivalent atoms: ‘=x, y  1/2,
z + 3/2; ‘‘=x  1, y, z.
Fig. 2. Structure of a tetrameric unit of 1. Ag–Ag interactions shown as dashed lines
and atoms generated by symmetry operations are indicated by: ‘ = 1  x, 1  y,
1  z.
Fig. 3. Two subunits of 1 linked by bridging DMSO ligands (carbon atoms of the 9-
aca ligands omitted for clarity). Ag–Ag interactions shown as dashed lines and
atoms generated by symmetry operations are indicated by: ‘ = 1  x, 1  y, 1  z and
‘‘ = x, 1  y, 1  z.
Fig. 4. Perspective view of [Ag(2-Me-imH)2(9-aca)] (2).
184 M. McCann et al. / Polyhedron 56 (2013) 180–188Ag–N bonds in [Ag6(imH)4(9-aca)6(MeOH)2] (2.088 Å). As is the
case in the latter two complexes, the imidazole ligands in 2 are
coordinated approximately linearly to each other (N(31)–Ag(1)–
N(21) bond angle of 162.07(9)) with the 9-aca ligand almost per-
pendicular (N(31)–Ag(1)–O(1) bond angle of 96.93(8)). The silver
ion does not interact significantly with other donors or with neigh-
bouring silver ions (closest Ag  Ag distance is 4.1930(5) Å). The
methyl groups at the 2-position on the imidazole ring are in a
cis-conformation to each other and lie approximately perpendicu-
lar to the plane of the anthracene ring (Fig. 5).
Three sets of interactions define the packing of the molecules in
the crystal lattice. The non-coordinated carboxylate oxygen atom
(O2) is hydrogen bonded to the imidazole NH groups of two
neighbouring molecules (Fig. 5 and Table 2), this generates athree-dimensional hydrogen bonded network. There are also two
sets of p–p interactions: First the imidazole groups on adjacent
molecules are paired (under 1  x, y, 2  z) so that the mean
Fig. 5. Intermolecular H-bonding (shown as dashed lines) in 2. Symmetry codes: /
½ + x, ½  y, ½ + z; // x, y, ½ + z; /// ½ + x, ½  y, ½ + z; //// x, y, ½ + z.
Fig. 6. Packing diagram for 2 showing pp interactions (hydrogen bonds shown as
dashed lines).
Fig. 7. Perspective view of (2-Mebenz-imH2)(9-aca)H2O (5). Dashed lines repre-
sent hydrogen bonds.
M. McCann et al. / Polyhedron 56 (2013) 180–188 185interplanar distance is 3.33 Å and the centroid–centroid distance is
3.52 Å. Neighbouring anthracene groups are also paired, with p–p
overlap of their outer rims (C8–C12 and C10–C10, 3.354 and
3.363 Å, respectively under symmetry operation ½  x, ½  y,
2  z). Together, these interactions generate p–p-linked chains
parallel to the ab diagonals (Fig. 6).
The IR spectrum of 2 has bands at 3047 and 1113 cm1 repre-
senting the N–H and C–N stretching vibrations of the imidazole li-
gand, respectively. Bands are also evident at 1622, 762 and
734 cm1 for the vibrations of the anthracene ring system
[12,14]. The m(OCO)asym and m(OCO)sym vibrations occur at 1590 and
1421 cm1, respectively, giving a D(OCO) value of 169 cm1.
The 1H NMR spectrum of [Ag(2-Me-imH)2(9-aca)] (2) exhibits
peaks for the anthracene protons in similar positions to those in
the spectra of [Ag2(9-aca)2] and [Ag4(DMSO)4(9-aca)4]n (1), with
additional peaks at 7.08 and 2.47 ppm for the imidazole ring and
methyl protons, respectively.
[Ag(4-Ph-imH)2(9-aca)] (3) was synthesised from [Ag2(9-aca)2]
and 4-phenylimidazole (4-Ph-imH) in good yield (81%) (Scheme 1).
The IR spectrum of 3 contains bands associated with the imidazoleand anthracene carboxylate ligands, with the m(OCO)asym and
m(OCO)sym vibrations occurring at 1553 and 1424 cm1, respectively
(D(OCO) = 129 cm1). In the 1H NMR spectrum of (3) the signals for
the anthracene protons appear in similar positions to those in
[Ag2(9-aca)2] and complexes 1 and 2. Peaks for the 4-Ph-imH pro-
tons appear at 7.88, 7.83, 7.59, 7.39 and 7.25 ppm and these are
shifted downfield in comparison to those observed in the spectrum
of the free ligand. Furthermore, peak integrals indicate that the ra-
tio of 9-aca:4-Ph-imH is 1:2. Thus, these combined IR, NMR and
microanalytical data suggest that 3 may be structurally similar to
[Ag(2-Me-imH)2(9-aca)] (2).
Spectral and microanalytical data for [Ag(2-Mebenz-imH)2(9-
aca)] (4), which was synthesised in high yield from [Ag2(9-aca)2]
and 2-methylbenzimidazole (2-Mebenz-imH) in acetonitrile, sug-
gests that this complex is isostructural with 2 and 3.
In an attempt to recrystallise [Ag(2-Mebenz-imH)2(9-aca)] (4)
from ethanol the silver-free, monohydrate salt, (2-Mebenz-
imH2)(9-aca)H2O (5), crystallised and was subsequently charac-
terised using X-ray crystallography (Fig. 7). The cationic nature of
the benzimidazolate was established from difference electron den-
sity maps which clearly showed the NH protons. The bond lengths
and geometry are as expected for a benzimidazolate cation and
carboxylate anion. The water molecules link 9-aca anions into
chains parallel to the a axis and the benzimidazolate cations link
the chains by hydrogen bonds to water and to one of the carboxyl-
ate oxygen atoms (Fig. 8, Table 2). The 2-Mebenz-imH2+ cations lie
between the 9-aca anions generating p-stacked columns, also
running parallel to the a axis (Fig. 8) and linking the structure into
sheets. The interplanar distances between the mean plane of the
benzimidazolate cation and the neighbouring anthracene ring are
3.16 and 3.51 Å (under symmetry operation x  1, y, z).
[Ag(2-Mebenz-im)] (6) was synthesised from [Ag2(9-aca)2] and
2-methylbenzimidazole in methanol and the product formed in
good yield (79%) (Scheme 1). The small changes in the reaction
Fig. 8. Packing diagram for 5 showing hydrogen bonds (dashed) and p-stacking.
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aca)2 (4) (methanol as opposed to acetonitrile and elevated tem-
perature), has led to a product that is structurally quite different
and an absence of the 9-aca anion. Although the IR spectrum of
6 contained bands for the imidazolate ligand, distinctive bands
for the carboxylate moiety were not observed. Microanalytical data
indicate a Ag:2-Mebenz-im ratio of 1:1 and that the imidazole has
been deprotonated at the amine nitrogen (N–H) atom to form the
anion, 2-Mebenz-im.
[Ag(Benz-im)] (7), [Ag(2-Ph-im)] (8) and [Ag(4,5-CN-im)] (9)
formulate in a similar manner to 6, and the 1H NMR spectrum of
the only sparingly soluble complex, (8), contained peaks for the
2-Ph-im anion and no aca- peaks were observed. It is thought that
these largely insoluble materials, (6–9), form as polymeric chains
in which the silver is coordinated to the deprotonated amine N
of one imidazolate ligand and the imine nitrogen of a neighbouring
imidazolate ligand (Fig. 9). Similar polymeric chains have been re-
ported for the silver(I)–4-nitroimidazolate complex, [Ag(4-NO2-
im)] (4-NO2-imH = 4-nitroimidazole) [15], and also for metal-imi-
dazolate complexes of Ni(II), Cu(II), Zn(II) and Ag(I) [14].
In the syntheses of 1–9 it is interesting to note the influence of
the pKa of the imidazole ligand and also the reaction solvent. As ex-
pected, imidazoles with relatively low pKa values (Benz-imH pKa
5.4; 2-Ph-imHpKa 5.23; 4,5-CN-imHpKa 5.2) had a greater tendency
to deprotonate (yielding the imidazolate complexes 7, 8 and 9,
respectively). The presence of a coordinating metal ion will also
lower the pKa of the imidazole [16,17]. With 2-Me-imH, 4-Ph-imH
and 2-Mebenz-imH (pKa values of 7.75, 6.1 and 6.19, respectively)
the imidazole ligand remains neutral and the respective imidaz-
ole/carboxylate complexes, 2, 3 and 4, form from [Ag2(9-aca)2]
when the reactions are conducted in the polar, aprotic solvent,
MeCN. In the reaction of [Ag2(9-aca)2] with 2-Mebenz-imH the sol-
vent appears to also be an important factor as the protic solvent,
MeOH, promotes formation of the imidazolate complex, [Ag(2-Me-
benz-im)] (6) and, presumably, the free carboxylic acid, 9-acaH. TheNN
R1
R2R
3
N N
R1
R2 R3
AgAg
NN
R1
R2R
3
N N
R1
R2 R3
AgAg
Fig. 9. Proposed polymeric structure for imidazolate complexes 6–9.tenuous nature of [Ag(2-Mebenz-imH)2(9-aca)] (4) is exemplified
by the fact that dissolution in refluxing EtOH causes complex disin-
tegration and formation of the imidazolium salt, (2-Mebenz-
imH2)(9-aca).
3.2. Biological activity
The growth inhibitory effects of the new Ag(I) complexes,
AgNO3 and silver sulphadiazine were investigated against Gram-
negative E. coli., Gram-positive MRSA and the fungal pathogen, C.
albicans (Table 3). For direct comparisons with AgNO3 and silver
sulphadiazine the activities (as MIC50 or MIC100 values) are re-
ported as lM concentrations of administered Ag(I) ion. The me-
tal-free ligands were also screened and all proved to be inactive
at the relatively high concentration of 100 lg cm3.
In all cases, the complexes were substantially more active
against the fungal cells than the two bacterial species, a pattern
which matched that previously observed with the N1-substituted
imidazole/9-aca Ag(I) complexes [6]. These results are somewhat
at variance with those observed for the Ag(I) complexes containing
2-hydroxymethyl-N-alkylimidazole ligands where, dependant on
the chain length of the alkyl substituent on the imidazole, the
activity against E. coli, S. aureus and B. spirizizenii exceeded that
for C. albicans [5]. In terms of Ag(I) content, there was no significant
difference in the antibacterial and antifungal activities of 1–4 and 6
compared to those of the Ag(I) complexes containing N1-substi-
tuted imidazole and 9-aca ligands [6]. The insoluble, imidazolate
complexes, 7–9, were a lot less aggressive towards bacteria than
the other Ag(I) complexes. Complexes 6–8 were the least active
against C. albicans whilst the other Ag(I) complexes were ca. twice
as active as the prescription drug, Ketoconazole (MIC100 = 4.70 lM)
[6].
The insect larvae, G. mellonella, was used to conduct in vivo tox-
icity profiling on the new Ag(I) complexes and results were com-
pared to an untreated control (no added compound) and also to
the reference standards, silver nitrate and ketoconazole. Test solu-
tions/suspensions (100 lg cm3) were injected directly into the
haemocoel through the last pro-leg of the insect and survival
was monitored after 72 h. Death was confirmed by the lack of
movement in response to stimulus together with discolouration
of the cuticle. Two types of in vivo antifungal screening protocols
were examined: (i) prophylactic treatment and (ii) the treatment
of infection (pre-infected larvae). Larvae were infected with a
lethal dose of C. albicans (2  106 fungal cells) in each protocol.
For the prophylactic treatment, the test compound was adminis-
tered 1 h prior to infection with C. albicans cells, while for the treat-
ment of infection experiments the compound was administered
1 h after infection with C. albicans. Results are given in Table 4.
For the prophylactic treatment, all of the test complexes, with
the exception of [Ag(2-Me-im)2(9-aca)] (2), offered a substantially
greater chance of survival, in comparison to the untreated control,
against infection by a lethal dose of C. albicans. When analysed in
terms of lg cm3 of compound, AgNO3 and ketoconazole gave
the best protection. [Ag(2-Ph-im)] (8) proved to be the most effi-
cient of the new Ag(I) complexes which is somewhat surprising
since this complex registered one of the higher MIC100 values
(6.21 lM; 1.56 lg cm3) in the in vitro testing against the fungus.
For the treatment of infection, AgNO3 and ketoconazole again of-
fered the best prognosis. Sample 2 and the more insoluble materi-
als, 6–9, proved to be the most active of the new complexes.
Overall, the survival rates of larvae treated with AgNO3 were
very similar in the prophylactic and the treatment of infection
experiments (80% and 75%, respectively). However, whereas com-
plex 2 did not offer significant protection when administered
prophlytically (30% survival) it proved to be extremely beneficial
when used to treat larvae that had been pre-infected with C. albi-
Table 3
Antimicrobial activities of the new Ag(I) complexes and the positive controlsa, AgNO3 and silver sulfadiazine. MIC values are given in lM concentrations of Ag(I) ions.
Complex E. coli MIC50 (lM Ag+) MRSA MIC50 (lM Ag+) C. albicans MIC100 (lM Ag+)
[Ag4(DMSO)4(9-aca)4]n (1) 22.12 22.38 1.92
[Ag(2-Me-imH)2(9-aca)] (2) 22.87 34.54 1.58
[Ag(4-Ph-imH)2(9-aca)] (3) 50.21 76.08 2.53
[Ag(2-Mebenz-imH)2(9-aca)] (4) 25.96 29.82 2.62
[Ag(2-Mebenz-im)] (6) 36.14 52.21 13.07
[Ag(Benz-im)] (7) 138.93 171.73 6.93
[Ag(2-Ph-im)] (8) 149.77 76.08 6.21
[Ag(4,5-CN-im)] (9) 127.22 244.49 1.73
AgNO3 65.19 34.32 1.83
Silver sulfadiazine 73.05 50.20
MIC100 for Ketoconazole against C. albicans is 4.70 lM [6].
a Previously published [6].
Table 4
Survival (%) of G. mellonella larvae 72 h after being infected with a lethal dose of C. albicans (2  106 fungal cells). For prophylactic
treatment, the test compound was administered 1 h prior to infection with C. albicans cells, while for the treatment of infection
experiments the compound was administered 1 h after infection with the fungal cells. Compounds were administered at a
concentration of 100 lg cm3). Data for the control, silver nitrate and ketoconazole have previously been published [6].
Test compound Dosage lg cm3 (lmol Ag(I) cm3) % Survival
Prophylactic Treatment of infection
Control 10 10
Ketoconazole 100 (0) 75 75
Silver nitrate 100 (0.59) 80 75
1 100 (0.49) 50 30
2 100 (0.20) 30 70
3 100 (0.21) 45 20
4 100 (0.22) 40 10
6 100 (0.42) 40 50
7 100 (0.44) 60 50
8 100 (0.39) 70 60
9 100 (0.44) 60 60
M. McCann et al. / Polyhedron 56 (2013) 180–188 187cans (70% survival). This suggests that there may be substantial
degradation of the complex in the 1 h timeframe between complex
administration and inoculation with the lethal dose of fungal cells.
This trend contrasted with that of complex 4 (40% prophylactic,
10% treatment of infection).
The trends found for the two sets of in vivo experiments using G.
mellonella closely reflect those observed using Ag(I) 9-anthracene
carboxylate complexes containing N1-substituted imidazoles [6],
where again, AgNO3 proved to be the most effective agent. This im-
plies that the position of substituents on the imidazole ring does
not impact greatly on the activity of the Ag(I) complex.
In the current work, when the survival figures are analysed with
respect to the Ag(I) ion content of each complex it is evident that
complexes 3 and 2 performed the best in the prophylactic and
treatment of infection experiments, respectively (activities are ca
1.5 and 3 times that of AgNO3). In terms of Ag(I) ion content, [Ag4(-
DMSO)4(9-aca)4]n (1), which does not contain an imidazole ligand,
returned one of the poorest performances.4. Conclusions
[Ag2(9-aca)2] reacts with DMSO and a selection of substituted
imidazoles giving [Ag4(DMSO)4(9-aca)4]n (1), [Ag(2-Me-imH)2(9-
aca)] (2), [Ag(4-Ph-imH)2(9-aca)] (3), [Ag(2-Mebenz-imH)2(9-
aca)] (4), [Ag(2-Mebenz-im)] (6), [Ag(Benz-im)] (7), [Ag(2-Ph-
im)] (8) and [Ag(4,5-CN-im)] (9). In the carboxylate/imidazole
complexes 2–4, the imidazole ligand remains neutral, whilst in
6–9 the imidazolate ligand deprotonates and no carboxylate ligand
is present. Refluxing 4 in EtOH gives the metal-free, imidazolium
salt, 2-Mebenz-imH2)(9-aca)H2O (5). The Ag(I) complexes are very
active against C. albicans, and moderately active against MRSA andE. coli. A number of the complexes offer a good prognosis for G.
mellonella infected with a lethal dose of C. albicans cells.
Appendix A. Supplementary data
CCDC 920488–920490 contain the supplementary crystallo-
graphic data for compounds 1, 2, and 5, respectively. These data
can be obtained free of charge via http://www.ccdc.cam.ac.uk/con-
ts/retrieving.html, or from the Cambridge Crystallographic Data
Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-
336-033; or e-mail: deposit@ccdc.cam.ac.uk. Supplementary data
associated with this article can be found, in the online version, at
http://dx.doi.org/10.1016/j.poly.2013.03.057.
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